🇺🇸 FDA
Patent

US 8093403

Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same

granted A61PA61P13/08A61P15/00

Quick answer

US patent 8093403 (Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same) held by Takeda Pharmaceutical Company Limited expires Mon Jan 05 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Jan 10 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 05 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61P, A61P13/08, A61P15/00, A61P17/14, A61P35/00